Medindia

X

Prevalence of Type 2 Diabetes in India is Among the Highest in the World and Growing

Thursday, October 16, 2008 General News J E 4
Advertisement
Insulins and Other Expensive Agents Are Out of Reach of Most Indian Patients, According to a Report From Decision Resources



WALTHAM, Mass., Oct. 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the prevalence of type 2 diabetes in India is among the highest in the world with more than 28 million cases in 2007. Prevalence will grow more rapidly in India than in any other developing or developed nation, climbing to more than 60 million cases by 2017.



The new Emerging Markets report entitled Type 2 Diabetes in India, forecasts that the Indian type 2 diabetes drug market will double from $504 million in 2007 to more than $1.1 billion by 2012. This growth will be fueled by rising disease prevalence, increasing wealth and growing awareness of the disease and diabetic complications.



"Although awareness of type 2 diabetes has increased thanks to the efforts of public health officials and Indian and Western pharmaceutical companies, the low rate of diagnosis continues to be a challenge for physicians," said Donny Wong, Ph.D., Principal Analyst at Decision Resources. "Clinicians we interviewed emphasized that it is imperative to encourage at-risk persons to seek medical attention and to improve screening practices in India so that patients can be identified long before they develop diabetic complications."



The report also finds that widespread poverty puts treatment with Western branded drugs out of reach of most Indians, who rely instead on ayurvedic medicines (traditional and ancient Indian herbal medicine) or low-cost generics manufactured by Indian companies. Although many companies price their drugs according to the local market, most of the newest therapies, especially the insulin analogues, are too expensive for all but the burgeoning urban upper and upper-middle classes.



"Merck has priced Januvia at a considerable discount relative to its U.S. price--Rs 42 or $1.00 per day of therapy," added Dr. Wong. "However, even this price represents 13 percent of an average worker's daily wages and 64 percent of a minimum-wage earner's pay."



EMERGING MARKETS REPORTS

The Ultimate Analysis of Pharmaceutical Markets in China and India

Decision Resources is the FIRST and ONLY company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.



About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.



About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.



All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.



SOURCE Decision Resources
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Decision Resources, Inc. Named to the Inc. 5000 Li...
S
Masimo to Report Third Quarter 2008 Financial Resu...